Company director and former Enovate Medical exec chair and CEO Dr. Fred Parks has been named to take over Green’s position.
“Jim Green led Analogic during a period of meaningful development and growth, and we owe him a debt of gratitude. Jim had the vision and leadership skills to transform Analogic into the industry leader that we are today, and to position the company to capitalize on even greater opportunities in the future. We thank him for his commitment and achievements, and wish him success as he takes the next step in his career. Fred is a seasoned executive with broad experience in the medical technology industry, and he has the right skills to take Analogic to the next stage of growth. Fred’s experience running both larger and entrepreneurial growth companies in our industry will be invaluable as we grow our ultrasound, medical imaging, and security and detection businesses. In addition, Fred has proven success in developing and launching innovative products, creating effective sales teams and driving market penetration. We have made significant investments in Ultrasound and look forward to leveraging Fred’s leadership talents as we seek to unlock the potential value in that business,” board chair Bernard Bailey said in a press release.
“After nearly a decade at the helm of Analogic, it is time for me to explore new opportunities and pass the reins of the company to new leadership. Fred has the skills and experience to take the company to the next level. It is gratifying that someone I respect and trust as much as Fred will be succeeding me as President and CEO,” Green said in a prepared release.
“I am honored to be appointed by the board to build on Jim’s accomplishments at Analogic. We have exciting opportunities to capitalize on our investments in technology and our channel as we continue to execute on our fiscal 2017 plan and drive long term growth. I look forward to continuing to work with the board, our strong management team, and our dedicated employees as we satisfy an expanding base of customers and create greater value for our shareholders,” Parks said in a prepared statement.
The move will go into effect on November 22, after which the company said it will being a search for a permanent replacement for Upadhyay, according to an SEC filing.
CeloNova BioSciences said in September it appointed exec chair Dennert Ware as interim CEO, replacing Martin Landon who left the company to become CEO of BioBridge, effective October 1.
Senior veep and GC Jason Cone will take over as interim exec chair.
“Jason has been a very capable leader in the areas of regulatory, quality and clinical affairs, as well as business development, which have been critical to our recent success, and I have every confidence in his ability to guide the organization through this transition,” Ware said, according to the San Antonio Business Journal.
3DIcon said it is lifting its former veep of technology and biz dev Doug Freitag as its new CEO.
“I look forward to assuming this new role during an exciting time for 3DIcon as a company. Following the recent merger with Coretec Industries, we are well positioned to continue the further advancement of our own 3D volumetric display technology, CSpace. We are also excited to enter new, burgeoning markets that utilize Silicon-materials which we anticipate will result in near-term revenue to the company. I’d like to thank current 3DIcon leadership for inviting me to continue and expand my role within the Company, and am excited about our prospects moving forward,” Freitag said in a prepared release.
NanoVibronix said last month it tapped Brian Murphy as its new director and CEO, replacing William Stern, who will stay on as prez and board vice chair. The company also appointed Christopher Fashek as board chair, replacing Ira Greenstein, who will remain on as a member.
“We are pleased to announce the appointments of such proven industry executives, who will be valuable assets as we continue with product development, clinical trials for additional 510(k) clearances, a robust marketing program and securing additional distribution partners for our innovative ultrasound devices in the U.S. and Europe. We are confident that Brian Murphy is the most prepared person to lead the company moving forward given his significant sales, operational and business insight from his prior management experience in the medical device field. As President and Vice Chairman of the Board, I look forward to supporting Brian in his new role,” board vice chair & Prez Stern said in a press release.
The company tapped Dr. Louis Vaickus to advise the company on medical and regulatory issues until a new permanent chief medical officer can be found, according to an SEC filing.
“Dr. Schallhorn’s medical expertise is pivotal to our clinical and medical affairs strategy and our partnership with doctors, clinical advisors, academia, and ophthalmic associations. Dr. Schallhorn’s advisory will be essential for the continued advancement of our innovations in the most relevant clinical way for excellent performance and practice efficiency,” ophthalmic devices global prez Jim Mazzo said in a press release.
“Cathy Burzik brings extensive experience as a superb operator and a highly effective value creator in the healthcare industry. She has demonstrated the ability to apply innovative and strategic direction, leading to the creation of significant shareholder value. We welcome her and look forward to her contribution to our company’s success,” board chair Richard Meelia said in a prepared statement.
“Since we announced DeepMind Health earlier this year, we’ve been inundated with requests and suggestions from patients, nurses, doctors, researchers and Trusts. It’s clear there’s massive demand for new technology to help patient care, and many brilliant people across the NHS with practical ideas about how to make it happen. We also know that working in health is complicated, and we need many different types of expertise if we’re to build tools that have real clinical impact, integrate well with the needs and existing infrastructure of the NHS, and set ever higher standards for privacy and security. We don’t underestimate this challenge at all. Over the last year we’ve brought together some amazing leaders with diverse skills and experiences to join us on this mission. With continued input from and engagement with patients and clinicians across the country, we’ll be working hard to deliver on the promise of positive impact for the NHS and those, like us, who depend on it,” DeepMind cofounder Mustafa Salesman said, according to Business Insider.
Strata Skin Sciences (NSDQ:SSKN) said its prez & CEO Michael Stewart resigned from his position, including his membership on the company’s board. Stewart will stay on as a consultant with the company for 6 months, according to an SEC filing from the company.